Rituximab biosimilar - Bio Sidus S.A.
Latest Information Update: 16 Aug 2013
$50 / €47 *
At a glance
- Originator Bio Sidus S.A.
- Developer Biosidus S.A.
- Class Antineoplastics; Antirheumatics; Monoclonal antibodies
- Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase Unknown Immunological disorders; Non-Hodgkin's lymphoma; Transplant rejection
Most Recent Events
- 15 Aug 2013 Investigation in Immunological disorders in Argentina (Parenteral)
- 15 Aug 2013 Investigation in Non-Hodgkin's lymphoma in Argentina (Parenteral)
- 15 Aug 2013 Investigation in Transplant rejection (prevention) in Argentina (Parenteral)